COMPOSITION FOR TREATMENT OF DIABETES CONTAINING A LONG-TERM ANALYZING CONSULATE AND A LONG-TERM ANSULINOTROPIC PEPTIDE CONJUGATE

摘要

1. A pharmaceutical composition for the prevention or treatment of diabetes, comprising a long-acting insulin conjugate and a long-acting insulinotropic peptide conjugate, wherein each of the long-acting insulin conjugate and a long-acting insulinotropic peptide conjugate is prepared by linking the insulin or insulinotropic peptide to the immunoglobulin Fc region via a non-peptidic linker selected from the group consisting of polyethylene glycol, polypropylene glycol, ethylene glycol-propylene glycol copolymer, gender oxyethylated polyols, polyvinyl alcohol, polysaccharide, dextran, polyvinyl ethyl ether, biodegradable polymer, lipid polymer, chitin, hyaluronic acid and their kombinatsii.2. The composition of claim 1, wherein the insulin is native insulin, basal insulin, a variant of insulin obtained by any of a substitution, insertion, deletion, modification of the amino acid sequences of native insulin, an insulin derivative or a fragment thereof, or a combination thereof. The composition of claim 1, wherein the insulin is modified by a non-peptidyl polymer. The composition of claim 3, wherein the non-peptidyl polymer is selected from the group consisting of polyethylene glycol, polypropylene glycol, ethylene glycol-propylene glycol copolymer, polyoxyethylated polyol, polyvinyl alcohol, polysaccharide, dextran, polyvinyl ethyl ester, biodegradable polymer, lipid polymerized polymer, lipural polymer .5. The composition according to claim 1, where the insulinotropic peptide is selected from the group consisting of GLP-1 (glucagon-like peptide-1), exendin-3, exendin-4, their agonists, their derivatives